In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging-providing evidence of a reduction in the incidence of HCMV viraemia-they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.
| INTRODUCTION

Human cytomegalovirus (HCMV) is an important opportunistic pathogen in patients undergoing solid organ transplantation (SOT).
The natural history of HCMV infection in these patients is complex. 1 Recipients who have HCMV-specific IgG antibodies before transplant (seropositives; R+) are at risk of reactivating virus once they receive immunosuppressive drugs. They are also at risk of reinfection if a different strain of HCMV is transferred from a seropositive donor organ (D+). Recipients who are seronegative (R−) may also acquire primary infection from a seropositive donor organ. 1, 2 After transmission, viral replication in the recipient leads to the appearance of HCMV DNA in the blood (viraemia), reflecting an increased potential to disseminate HCMV causing a variety of end-organ diseases, which is directly related to higher viral loads. 2, 3 The ability of HCMV to reactivate from latency and reinfect seropositive individuals, along with the threat of primary infection, means the risk of infection is so high, and the risk of disease so serious, that transplant centers routinely employ 1 of 2 strategies to use ganciclovir or its oral prodrug valganciclovir to prevent HCMV end-organ disease. 4 For the strategy of prophylaxis, patients are given drug from the time of transplant onward for a fixed period of time, with clinical trials supporting duration of prophylaxis of 100 days or 200 days. 5, 6 This strategy effectively prevents end-organ disease for these periods of time, but patients remain at risk of developing viraemia, and late onset disease once prophylaxis is stopped. 7 This is a particular problem in the high risk D + R− subgroup where a recipient without natural immunity receives an organ from a seropositive donor. 7 In some cases, late onset disease is caused by strains of HCMV that have developed resistance to ganciclovir, which requires the use of increasingly toxic second line therapies. 8, 9 For the strategy of preemptive therapy, no patient receives prophylaxis and drug is only administered to those where surveillance samples detect viraemia above a threshold value defined by real-time polymerase chain reaction (PCR). 2 Preemptive therapy is typically stopped when a patient has 2 consecutive blood samples where HCMV DNA is undetectable. 2 Surveillance for infection continues, and some patients develop a second episode of viraemia, which is again treated until viraemia becomes undetectable. Thus, one clear
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Occasional patients develop resistant strains of HCMV.
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These 2 strategies are equally effective at preventing end-organ disease as shown by a meta-analysis by the Cochrane collaboration of the 7 controlled trials that have randomized SOT patients to be managed by either prophylaxis or preemptive therapy. 11 As a consequence, both strategies are recommended in clinical guidelines as suitable ways of preventing HCMV end-organ disease. 4 The values seen in the 3 patient groups are highly significantly different, but we emphasize that there is substantial overlap so that the viral load results in a single individual cannot distinguish among primary infection, reinfection, or reactivation. 2 The availability of these rigorously defined biomarkers allows clinical trials to be designed so that the values can be used as pharmacodynamic assessments of whether or not prototype HCMV immunological interventions given pretransplant or peritransplant can control the extent of virus replication post transplant. Three randomized controlled trials have been conducted to date as reviewed below.
| RESULTS FROM RELEVANT CLINICAL TRIALS
In 1984, a single dose of a live attenuated vaccine based on the Towne strain of HCMV was given to seronegative and seropositive candidates awaiting renal transplantation. 12 This vaccine did not reduce the incidence of HCMV infection or the incidence of HCMV end-organ disease after transplant (Table 1A) . However, it appeared to reduce the severity of disease, although the Phase 2 clinical trial was not powered to provide statistical significance in selected subsets of patients (Table 1B and Figure 1 ). In light of our current understanding of the pharmacodynamics of HCMV in these patients, we would interpret these results as the vaccine reducing the peak viral load and its associated risk for disease, but PCR and quantitative measures of HCMV viraemia were not available at that time. However, it is clear from the study that the vaccination strategy did not interrupt transmission of HCMV, so how did it influence severity of disease? When peak viraemia is plotted against risk of end-organ disease, a sigmoid curve is obtained. 13, 14 The fact that both groups developed end-organ disease suggests that they both crossed this threshold value, allowing the virus to disseminate to those organs. It is not known if receipt of an even higher dose of virus could increase the severity of disease, but this is one possible explanation for the benefit produced by the Towne vaccine; that is, it reduced the effective inoculum. Alternatively, both groups of patients may have received the same dose of virus, but the recipients of Towne vaccine were better able to control virus replication, because their immune systems had been primed, limiting the severity of end organ disease.
In 2011, a vaccine comprising soluble recombinant glycoprotein B (gB) together with MF59 adjuvant was given to seronegative and seropositive candidates awaiting transplantation of a kidney or a liver. 15 The rationale for this choice of immunogen is that gB is an important structural determinant of virus entry into cells and represents a major target of the humoral response against HCMV in healthy seropositives. Importantly, when compared with placebo recipients, the vaccine appeared to reduce key markers of viral load post transplant. 15 Again, this Phase 2 study was not powered to provide statistical significance in subsets of patients, but the apparent rate of transmission of HCMV from donor to recipient was reduced ( Table 2 ). The titer of antibodies induced by the vaccine was reported as a correlate of protection, because it was significantly inversely associated with the duration of viraemia. 15 The numbers of patients in subgroups are limited, but the fact that there was no apparent effect on reactivation but the biomakers in those at risk of either reactivation or reinfection were lower suggested that reinfection was reduced in the D + R+ subgroup (Table 2 ). This potential explanation of reduced exogenous infection was seen even more clearly in the D + R− subgroup at risk of primary infection (Table 2) . Thus, the gB/MF59
vaccine used in this study may have interrupted transmission of HCMV from the donor to both seronegative and seropositive recipients. Genentech organized and conducted a multicenter, multinational randomized controlled trial to recruit 120 patients and published the results in 2017. 17 These results were consistent with the hypothesis that humoral immunity can prevent transmission of HCMV from the donor organ to cause clinically significant HCMV viraemia in the posttransplant period (Table 3 ). In addition, the study reported significantly reduced CMV syndrome in the recipients of the mAbs. 17 An important conclusion from this application of passive immunity is that measurements of concentrations of mAbs found in recipients inform the target level that active immunization with the relevant antigen should also aim to achieve. The values are plotted but not reported in the supporting information of the paper describing the clinical trial but can be inferred from the earlier Phase 1 study that gave the same dose (10 mg/kg each) of the same mAbs to normal volunteers (Table 4A and B) . 17, 18 The half-life was given as 26.9 and 27.4 days in the renal transplant recipients, which is very similar to the values in Table 4A and B. Thus, the pharmacokinetic parameters shown in Table 4A and B provide direct values of antibody Serial blood samples were tested for cytomegalovirus DNA by real-time quantitative PCR (rtqPCR). Viraemia was defined as a blood sample that was PCR positive (cutoff 200 genomes per mL whole blood). Any patient with 1 blood sample containing more than 3000 cytomegalovirus genomes per mL received ganciclovir until 2 consecutive undetectable cytomegalovirus DNA measurements. While these caveats hinder effective retrospective analyses of previous studies, there are currently a series of HCMV vaccines in various stages of clinical evaluation, and some may be studied in the SOT setting. 20 We propose that the novel possibility of interrupting transmission of HCMV should be examined in all future studies of active and passive immunization against HCMV and suggest the following 5 criteria for assessment.
| Evidence of HCMV infection in body compartments additional to blood
Before PCR became available, surveillance samples of urine and saliva were collected from transplant recipients and tested by conventional cell culture or rapid cell culture confirmation methods to detect HCMV. 21 The sensitivity for predicting future HCMV end-organ disease was good, but the positive predictive value was low, because most people with HCMV in the urine or saliva did not develop and-organ disease. 21 The same was true when urine and saliva samples were tested by PCR. 22 Methods based on PCR were able to detect the lower levels of HCMV found in blood and had a better positive predictive value than either urine or saliva and so replaced these earlier diagnostic methods.
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However, in the modern era, detection of HCMV in saliva and urine could be used as sensitive methods of identifying active infection in the salivary glands and kidneys, respectively. The observation of serial negative PCR results from saliva and urine in an individual patient would then support the conclusion that HCMV had not been transmitted from the donor.
In our hands, the results of following hundreds of D-R-transplant patients for evidence of viraemia consistently show an absence of RG7667 is a combination of 2 monoclonal antibodies, one reactive with glycoprotein H and the second reactive with the protein from UL131. The proportion of patients with CMV viremia (viral load of ≥150 copies/ mL) measured by quantitative PCR and the proportion of patients with CMV syndrome are shown for the follow-up period of 24 weeks post transplant. Cytomegalovirus syndrome was defined as the presence of CMV in the blood and at least 1 of the following: fever, new or increased malaise, leucopenia, atypical lymphocytosis, or thrombocytopenia. End organ CMV disease was defined as presence of CMV in the blood and at least 1 of the following: localized CMV infection confirmed in a biopsy or other specimen and relevant symptoms or signs of organ dysfunction unlikely to be due to other causes. If the vaccine was designed or known to induce T cell responses, then assays with specificity for antigens not present in the vaccine would have to be used; again, this would require manufacturers of attenuated vaccines to delete nonessential genes.
| Evidence of human cytomegalovirus latency in recipients
A key biological characteristic of HCMV is the establishment of latency and would represent a clear marker of transmission from a donor to a seonegative recipient. Long-term follow-up of patients posttransplant could include an analysis for viral latency in individuals without viraemia. Isolation of monocytes from peripheral blood would allow a simple analysis for the presence of viral DNA and also a viral transcript landscape consistent with latent infection. 25, 26 True latency is defined by the capacity of the virus to reactivate, which can be done using in vitro stimulation of monocytes, although this would represent an attractive additional analysis rather than a mandatory one. 25, 27 Again, the power of sequencing could be harnessed, whereby a clear demonstration that the recipient strain matched that of the donor would strongly support transmission from a seropositive donor.
Conversely, repeatedly negative samples from a recipient would be consistent with the possibility that transmission of donor virus had been successfully prevented. • Donor samples should be collected where possible pretransplant, e.g., in live-related organ transplant to allow a genetic characterization of this virus.
• Urine and saliva as well as blood should be collected at every posttransplant visit to allow for monitoring of infection in different body compartments.
• A follow-up component of the study should be incorporated, perhaps as a substudy, to examine in detail those D + R− patients who do not have viraemia post transplant. They should be followed to see if they seroconverted and have the tests discussed above applied. As a way of controlling costs, samples could be stored prospectively and only tested if likely to be informative.
| WHY IS THIS SUBJECT IMPORTANT?
While the development of a vaccine that prevents overt disease in a number of clinical settings is paramount, it is highly desirable that any HCMV vaccine also interrupts transmission of virus. If administered to the general population, such a vaccine would have dramatic implications for young women of child bearing age given the devastating consequences associated with congenital HCMV infection. 35 The results have inherent scientific value as they will help to differentiate between complete interruption of transmission and merely reduction in the effective inoculum. A more complete understanding of the process that leads to transmission can only help the design of future studies that aim to inhibit it. Our current working hypothesis is that cells in the donor organ harboring latent HCMV are stimulated by inflammation and cytokine storm at the time of transplantation to reactivate HCMV (D+). 36 Starting from only a small number of cells, HCMV infection proceeds to infect other cells, to spread from the local site of replication and then to cause viraemia. 37, 38 The immune system may be able to contain this process at the site of transplant by attacking individual virions or infected cells before virions are released.
We propose that the latter target is a more plausible way of explaining how preformed antibodies could prevent transmission of infection from the donor to the recipient. The immunological mechanism responsible may therefore include processes like antibody dependent cellular cytotoxicity in addition to the more conventionally studied virus neutralization if cell-associated virus is to be targeted by the humoral antibody response plus innate NK immunity.
The results may also reveal new correlates of protection and/or mechanistic correlates of protection. 39 For example, the inverse relationship between the duration of viraemia and the titer of antibodies against gB identified these antibodies as a correlate of protection. 15 However, the mechanistic correlate might have been, for example, CD4 cells specific for HCMV with their contribution to T-help for B-cells explaining the correlation with protection seen for antibody titer. That said, the complementary randomized controlled trial of infusion of mAbs demonstrates that humoral immunity can be protective and likely elevates the titer of gB antibodies into the category of a mechanistic correlate of protection. 17, 39 More direct support for gB antibody responses will require studies directly infusing mAbs against gB into recipients-the mAbs infused in the Genetech trial were not specific for gB but for components of 2 major complexes on the surface of the virion (gH and UL131). 17 We thus propose that any mAbs that recognize HCMV proteins displayed on the surface of infected cells should be considered candidates for clinical evaluation. 40 The follow-up studies proposed could also prove important to give advice to recipients who received an experimental vaccine and now require a second transplant. Do they have any long-term immunity against HCMV? Do they harbor latent HCMV and thus will they reactivate HCMV once given high-dose immunosuppressive drugs like basiliximab that they are not currently receiving as maintenance Finally, an extension of these analyses will provide another parameter to allow preemptive therapy to be compared with prophylaxis. For example, we are not aware of any studies showing that prophylaxis prevents transmission of virus from the organ donor.
Certainly, some recipients get viraemia when prophylaxis is stopped, arguing that these individuals have been infected. 7 However, if prophylaxis did impact on transmission, then that could be assessed as a potential benefit.
In conclusion, maximizing our understanding from the clinical trials performed with current vaccine candidates has the potential to provide novel insight into the natural history of this virus alongside the clear implications for iterative improvements to the vaccines themselves.
